Predictive Value of the Fluorescent Cytoprint Assay (FCA): A Retrospective Correlation Study of In Vitro Chemosensitivity and Individual Responses to Chemotherapy

References

• Carney D. N., Winkler C. F. In vitro assays in chemotherapeutic sensitivity. Important Advances in Oncology, V. T. DeVita, Jr, S. Hellman, S. A. Rosenberg. JB Lippincott, Philadelphia 1981; 78–103
   Google Scholar
• DeVita V. T., Jr. Principles of chemotherapy. Cancer: Principles & Practice of Oncology, V. T. DeVita, Jr, S. Hellman, S. A. Rosenberg. JB Lippincott, Philadelphia 1989; 276–300
   Google Scholar
• Frei E. The national cancer chemorherapy program. Science 1982; 217: 600–606
   PubMed Web of Science ®Google Scholar
• Weisenthal L. M., Lippman M. E. Clonogenic and nonclonogenic in vitro chemosensitivity assays. Cancer Treat Rep 1985; 69: 615–632
   PubMedGoogle Scholar
• Von Hoff D. D. He's not going to talk about in vitro predictive assays again, is he?. Natl Cancer Inst 1990; 82: 96–101
   Google Scholar
• Rotman B., Teplitz C., Dickinson K., et al. Individual human tumors in short-term microorgan cultures: Chemosensitivity testing by fluorescent cytoprinting. In Vim Cell Dev Biol 1988; 24: 1137–1146
   PubMed Web of Science ®Google Scholar
• Rotman B., Papermaster B. W. Membrane Properties of limammalian cells as studied by enzymatic hydrolysis of fluorogenic esters. Proc Natl Acad Sci (USA) 1966; 55: 134–141
   PubMed Web of Science ®Google Scholar
• Rotman B., Teplitz C., Dickinson K., et al. Histological evaluation of a novel method for separating malignant cells from human surgical Specimens. Proc Am Assoc Cancer Res 1987; 28: 423
   Web of Science ®Google Scholar
• Hryniuk W. M. The importance of dose intensity in the outcome of chemotkapy. Important Advances in Oncology, V. T. DeVita, Jr, S. Hellman, S. A. Rosenbag. JB Lippincott, Philadelplua 1988; 121–142
   Google Scholar
• Gazdar A. F., Steinberg S. M., Russell E. K., et al. Correlation of in vim drug-sensitivity testing results with response to chemotherapy and survival in extensive-stage small cell lung cancer: A prospective clinical trial. J Natl Cancer Inst 1990; 82: 117–124
   PubMed Web of Science ®Google Scholar
• Alberts D. S., Salmon S. E., Chen H., et al. Pharmacologic studies of anticancer drugs with the human tumor stem cell assay. Cancer Chemother pharmacol 1981; 6: 253–264
   PubMed Web of Science ®Google Scholar
• Schwartz H. S., Sodergren J. E., Ambaye K. Y. Actinomycin D: Drug wncentrations and actions in mouse tissues and tumors. Cancer Res 1968; 26: 192–197
   Google Scholar
• Tattersall M. HN, Sodergren J. E., Sengupta S. K., et al. Pharmacokinetics of actinomycin D in patients with malignant mehanoma. Clin Pharmacol 1975; Th-17: 701–708
   Google Scholar
• Trillet V., Lakhal M., Lang J. Cellular pharmacokinetics of daunorubicin. Uptake by leukemic cells in vivo. Eur J Clin Pharmacol 1985; 29127–29129
   Google Scholar
• Brenner D. E., Galloway S., Cooper J., et al. Improved high performance liquid chromatography assay of doxorubicin: Detection of circulating aglycone in human plasma and comparison with thin layer chromatography. Cancer Chemother Pharmacol 1985; 14: 139–145
   PubMed Web of Science ®Google Scholar
• Lehane L. K., Lane B. D. The immunophmnawlogy of bleomycin in man. Bleomycin: Current Status and New Developments, S. K. Carter. Academic Press, New York 1987; 143–150
   Google Scholar
• Gormley P. E., Bull J. M., LeRoy A. F., et al. Kinetics of cis-dichlorodia-mineplatinum. Clin Pharm Ther 1979; 25: 351–357
   PubMed Web of Science ®Google Scholar
• Patton T. F., Himmelstein K. J., Belt R., et al. Plasma levels and urinary excretion of filterable platinum species following bolus injection and IV infusion of cis-dichlorodiamineplatinum (II) in man. Cancer Treat Rep 1978; 62: 1359–1362
   PubMedGoogle Scholar
• Himmelstein K. J., Patton T. F., Belt R., et al. Clinical kinetics of intact cisplatin and some related species. Clin Pharm Ther 1981; 29: 658–664
   PubMed Web of Science ®Google Scholar
• Pfeffer M., Scalzo A. J., Nardella P. A. The absolute oral bioavailability and pharmacokinetics of etoposide. Etoposide: Current Stotus and New Developments, B. F. Issell, F. M. Muggia, S. K. Carter. Academic Press, New York 1984; 127–140
   Google Scholar
• Farina P., Manillo G., D'Incalci M. High performamx liquid Chromatogrephy detrrmination Of 4′-dimethylepipodphyllotoxin-9-(4, 6–0-ethylidene B-D-glucopyranoside) VP16–213) in human plasma. J chromatog 1981; 222: 141–145
   PubMed Web of Science ®Google Scholar
• Aherne G. W., Marks V. A radioimmunoassay for VP16–213 in plasma. Cancer Chemother Pharmacol 1982; 7: 117–121
   PubMed Web of Science ®Google Scholar
• Fraile R. J., Baker L. H., Buroker T. R., et al. Pharmacokinetics of 5-fluorouracil administered orally, by rapid intravenous and slow infusion. Cancer Res 1980; 40: 2223–2228
   PubMed Web of Science ®Google Scholar
• Phillips T. A., Howell A., Grieve R. J., et al. Pharmawkinetics of oral and intravenous fluorouracil in humans. J Warm Sci 1980; 69: 1428–1431
   Web of Science ®Google Scholar
• Grochow L. B., Calvin M. Clinical pharmacokinetics of cyclophosphamide. Pharmacokinetics of Anticancer Agents in Humans, M. M. Ammes, G. Powis, J. S. Kovach. Elsevier Press, Amsterdam 1983; 135–154
   Google Scholar
• Farmer P. B., Newell D. R. Alkylating agents. Pharmacokinetics of Antiancer Agents in Humans, M. M. Ammes, G. Powis, J. S. Kovach. Elsevier Ress, Amsterdam 1983; 77–111
   Google Scholar
• Taha I. AK, Ahmad R. A., Gray H., et al. Plasma melphalan and prednisolone concenations during oral therapy for multiple myeloma. Cancer Chemother Pharmacol 1982; 9: 57–60
   PubMed Web of Science ®Google Scholar
• Schilcher R. B., Young J. D., Ratanstharathorn V., et al. Clinical pharmacokhetics of high dose mitomycin C. Cancer Chemother Pharmacol 1984; 13: 186–190
   PubMed Web of Science ®Google Scholar
• Reich S. D. Clinical pharmacology of mitomycin C. Mitomycin C: Current Status and New Developments, S. K. Carter, S. T. Carter. Academic Press, , NY 1979; 243–250
   Google Scholar
• Mellet L. B., Hodgson D. E., Woods L. A. Absorption and fate of 14C-labeled N,N',N triethylenethiophosphoramide (thioTEPA) in humans and dogs. J Lab Clin Med 1962; 60: 818–825
   PubMedGoogle Scholar
• Bender R. A., Castle M. C., Margileth D. A., et al. The pharmacokinetics of 3H-vincristine in man. Clin phannacol Ther 1977; 22: 430–438
   PubMed Web of Science ®Google Scholar
• Owellen R. J., Hartke C. A., Hains F. O. Pharmacokinetics and metabolism of vinblastine in humans. Cancer Res 1977; 37: 2597–2602
   PubMed Web of Science ®Google Scholar